Pure Biologics Spólka Akcyjna (WAR:PUR) — Stock Price
Pure Biologics Spólka Akcyjna (WAR:PUR) is currently trading at zł2.93 PLN, up 13.57% today. Over the past 52 weeks, shares have ranged between zł1.42 and zł7.70. This page tracks Pure Biologics Spólka Akcyjna's live share price on the WAR exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see PUR stock market capitalisation.
Pure Biologics Spólka Akcyjna (PUR) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Pure Biologics Spólka Akcyjna's daily closing share price and trading volume on the WAR exchange over the past year, giving a clear view of recent price momentum and liquidity.
Pure Biologics Spólka Akcyjna Income Statement — Revenue, Profit & Earnings by Year
Pure Biologics Spólka Akcyjna's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | zł0.00 | zł95.00K | zł662.00K | zł254.00K | zł572.00K |
| Cost of Revenue | zł46.00K | zł2.67 Million | zł6.07 Million | zł4.28 Million | zł273.00K |
| Gross Profit | zł-46.00K | zł-2.57 Million | zł-5.41 Million | zł-4.03 Million | zł299.00K |
| Research & Development | zł38.00K | — | zł23.79 Million | zł20.58 Million | zł18.39 Million |
| SG&A | zł3.99 Million | zł6.54 Million | zł8.03 Million | zł3.80 Million | zł6.01 Million |
| Total Operating Expenses | zł12.34 Million | zł29.14 Million | zł19.27 Million | zł6.46 Million | zł11.86 Million |
| Operating Income | zł-12.38 Million | zł-31.72 Million | zł-24.63 Million | zł-10.48 Million | zł-11.56 Million |
| EBITDA | zł-12.24 Million | zł-26.08 Million | zł-22.78 Million | zł-7.53 Million | zł-8.30 Million |
| EBIT | zł-12.38 Million | zł-31.86 Million | zł-25.27 Million | zł-10.45 Million | zł-11.41 Million |
| Interest Expense | zł1.33 Million | zł3.83 Million | zł329.00K | zł227.00K | zł349.00K |
| Income Before Tax | zł-13.19 Million | zł-35.69 Million | zł-25.60 Million | zł-11.77 Million | zł-11.76 Million |
| Income Tax Expense | — | — | zł769.00K | zł1.31 Million | zł349.00K |
| Net Income | zł-19.43 Million | zł-35.69 Million | zł-26.37 Million | zł-13.07 Million | zł-12.11 Million |
Pure Biologics Spólka Akcyjna Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Pure Biologics Spólka Akcyjna's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | zł2.34 Million | zł22.74 Million | zł33.01 Million | zł47.19 Million | zł18.94 Million |
| Total Current Assets | zł2.11 Million | zł21.60 Million | zł24.17 Million | zł43.02 Million | zł13.04 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | zł4.92 Million | zł26.75 Million | — |
| Net Receivables | zł1.63 Million | zł14.74 Million | zł15.22 Million | zł9.29 Million | zł1.35 Million |
| Inventory | — | — | — | zł0.00 | zł-1.00K |
| Property, Plant & Equipment | — | — | zł8.42 Million | zł3.45 Million | zł4.88 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | zł15.46 Million | zł20.84 Million | zł14.71 Million | zł7.70 Million | zł21.83 Million |
| Total Current Liabilities | zł15.46 Million | zł7.99 Million | zł12.83 Million | zł5.55 Million | zł18.00 Million |
| Long-term Debt | zł0.00 | zł12.72 Million | zł0.00 | — | — |
| Net Debt | zł13.75 Million | zł9.33 Million | zł602.00K | zł-3.06 Million | zł-3.95 Million |
| Total Stockholder Equity | zł-13.12 Million | zł1.89 Million | zł18.30 Million | zł39.49 Million | zł-2.89 Million |
| Retained Earnings | zł-112.36 Million | zł-92.93 Million | zł-57.23 Million | zł-31.63 Million | zł-19.87 Million |
Pure Biologics Spólka Akcyjna Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Pure Biologics Spólka Akcyjna generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | zł-10.83 Million | zł-23.26 Million | zł-17.39 Million | zł-24.04 Million | zł-1.35 Million |
| Capital Expenditures | zł0.00 | zł176.00K | zł5.76 Million | zł673.00K | zł561.00K |
| Free Cash Flow | zł-10.83 Million | zł-23.44 Million | zł-23.14 Million | zł-24.71 Million | zł-1.91 Million |
| Investing Cash Flow | zł3.56 Million | zł391.00K | zł15.35 Million | zł-28.48 Million | zł-561.00K |
| Financing Cash Flow | zł3.98 Million | zł24.22 Million | zł-1.88 Million | zł49.73 Million | zł-3.05 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | zł0.00 | zł1.30 Million | zł4.41 Million | zł2.79 Million | zł3.75 Million |
| Depreciation | zł309.00K | zł5.78 Million | zł2.50 Million | zł2.92 Million | zł3.11 Million |
| Change in Cash | zł-3.29 Million | zł1.35 Million | zł-3.92 Million | zł-2.78 Million | zł-4.96 Million |
Pure Biologics Spólka Akcyjna Earnings History — EPS Actual vs. Analyst Estimates
Track Pure Biologics Spólka Akcyjna's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2025 | -0.20 | — | — |
| Dec 31, 2024 | -1.69 | — | — |
| Sep 30, 2024 | -0.14 | — | — |
| Mar 31, 2024 | -0.89 | — | — |
| Dec 31, 2023 | -1.99 | — | — |
| Sep 30, 2023 | -1.41 | — | — |
| Jun 30, 2023 | -1.84 | — | — |
| Mar 31, 2023 | -1.37 | — | — |